ClinicalTrials.gg

Program

PRT13722

A development code.

Its studies are mostly in Breast Neoplasms, led by Prelude Therapeutics.

Furthest: phase 1, since Oct 15, 20261 company-led study, 1 open or runningNext primary completion: Oct 31, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Prelude Therapeutics11 open or runningphase 1since Oct 15, 2026Oct 15, 2026Oct 31, 2028phase 1 · NCT07905001

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 15, 2026First study: phase 1 study in Breast NeoplasmsFirst studyNCT07905001 · 242 planned · United States

Ahead

  1. Oct 31, 2028Primary completion: phase 1 study in Breast NeoplasmsNCT07905001

TargetBeta

KAT6A →read by rule
“A Phase 1/1b, First-in-Human, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PRT13722, a KAT6A Protein Degrader, as Monotherapy and in Combination With Endocrine and Targeted Therapy in Adults With Locally Advanced…”study text, by rule · the study

Other programs on KAT6A

ProgramCompanyFurthest phaseStudies
prifetrastatPfizerphase 310
KAT6A/B Inhibitor BG-75202ruleBeOne Medicinesphase 12
HRS-2189Jiangsu HengRui Medicinephase 12
KAT6 Inhibitor OP-3136ruleolema-pharmaceuticals-incphase 11
KAT6/KAT7 Inhibitor PF-08032562rulePfizerphase 11
KAT6/KAT7 Inhibitor IDE574ruleideaya-biosciencesphase 11
HLX97Fosun Pharmaphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07905001Breast Neoplasms · United States1RecruitingOct 31, 2028242

How it is read

Names in the registry

  • “PRT13722”, 1 entry

Codes read as this program: PRT13722.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.